FDA Recalls Epinephrine Injection Due to Sterility Assurance Failure
Central Admixture Pharmacy Services is recalling 3,338 bags of epinephrine injectable solution nationwide. The FDA raised concerns about sterility assurance during an inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of an injectable medication with no reported illnesses or injuries. The hazard—sterility assurance failure—is theoretical risk rather than confirmed contamination. Per the rubric, recalls with no reported illness/injury and theoretical hazards score at most 3 (High).
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 3,338 bags of epinephrine in dextrose 5% solution (2 mg/250 mL) due to sterility assurance issues.
The FDA conducted an inspection and determined that sterility could not be assured for these injectable products. Lack of sterility assurance in medications intended to be injected into patients poses a potential risk of contamination and infection.
The affected product was distributed nationwide in the United States. Eight lot numbers are affected, with expiration dates ranging from May 4, 2023 to June 29, 2023.
Healthcare facilities that received this medication should immediately stop using the affected lot numbers and contact the manufacturer for recall instructions.
The recalled product
- Product
- EPINEPHrine added to dextrose 5%, 2 mg/250 mL* (8 mcg/mL), 250 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-6030-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Compounded Injectable
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Lot # 37-884448
- Exp 05/04/2023
- 37-887386
- Exp 05/16/2023
- 37-888271
- Exp 05/21/2023
- 37-891189
- Exp 05/31/2023
- 37-893456
- Exp 06/11/2023
- 37-894656
- Exp 06/14/2023
- 37-898333
- Exp 06/28/2023
- 37-898559
- Exp 06/29/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27